Clinical trials
Non Small Cell Lung Cancer clinical trials
Below are recruiting non small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,401 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06472804Recruiting
Insomnia in advanced lung cancer patients
This study looks at how common insomnia (trouble sleeping) is in people with advanced lung cancer. It aims to better understand sleep problems so doctors can help patients sleep better.
Rochester, MinnesotaAges 18 years+ - NCT06476093Recruiting
Radiation plus anlotinib for lung cancer brain spread
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Lianyungang, JiangsuAges 18–80 - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06479473RecruitingPhase 1/Phase 2
Radiation for leftover spots after chemo-immunotherapy in lung cancer
This trial is for people with extensive-stage small cell lung cancer. After standard chemo-immunotherapy, it tests whether giving radiation to all remaining tumor spots can improve outcomes.
Hefei, AnhuiAges 18–70 - NCT06481566Recruiting
Almonertinib plus radiation for EGFR-mutant lung cancer
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06486142RecruitingPhase 3
Comparing targeted pills for EGFR-mutated lung cancer
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
LundAges 18 years+ - NCT06492421RecruitingPhase 2
Immunotherapy before surgery for lung cancer
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06495125RecruitingPhase 2
Study of three drugs for a type of advanced lung cancer
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Atlanta, GeorgiaAges 18 years+ - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT06496490RecruitingPhase 2
TQB2102 for HER2-mutated non-small cell lung cancer
This trial tests a new drug, TQB2102, for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene and has stopped responding to standard treatments. It aims to see if the drug can shrink or slow the cancer.
Fuzhou, FujianAges 18–75 - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06498986RecruitingPhase 2
BL-B01D1 plus osimertinib for EGFR-mutant lung cancer
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non small cell lung cancer?
- Yes. Clin2 currently lists 1,401 recruiting non small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Lung Cancer, Non-Small Cell
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.